In prostate cancer, the primary mechanisms for PI3K dysregulation are loss of function of PTEN through homozygous deletions, loss of heterozygosity, or inactivating mutations, leading to the constitutive activation of PI3K/Akt signaling. Here, AKT1 is linked to prostate carcinoma.